Evidence map›Paper›PMID 37638490›Full record

ArticleEuropean heart journal2024

Recommendations for statin management in primary prevention: disparities among international risk scores.

G B John Mancini, Arnold Ryomoto, Eunice Yeoh, Liam R Brunham, Robert A Hegele

Abstract read
In one paragraph

Article in European heart journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Review
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

G B John ManciniDepartment of Medicine, Division of Cardiology, Centre for Cardiovascular Innovation and Cardiovascular Imaging Research Core Laboratory (CIRCL), University of British Columbia, Rm 9111, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada.ORCID 0000-0002-2419-1476
Arnold RyomotoDepartment of Medicine, Division of Cardiology, Centre for Cardiovascular Innovation and Cardiovascular Imaging Research Core Laboratory (CIRCL), University of British Columbia, Rm 9111, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada.
Eunice YeohDepartment of Medicine, Division of Cardiology, Centre for Cardiovascular Innovation and Cardiovascular Imaging Research Core Laboratory (CIRCL), University of British Columbia, Rm 9111, 2775 Laurel Street, Vancouver, BC V5Z 1M9, Canada.
Liam R BrunhamDepartment of Medicine, Division of General Internal Medicine, Centre for Heart and Lung Innovation, University of British Columbia, Vancouver, BC, Canada.
Robert A HegeleDepartments of Medicine and Biochemistry, Division of Endocrinology, Robarts Research Institute, University of Western Ontario, London, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsStatin recommendations in primary prevention depend upon risk algorithms. Moreover, with intermediate risk, risk enhancers and de-enhancers are advocated to aid decisions. The aim of this study was to compare algorithms used in North America and Europe for the identification of patients warranting statin or consideration of risk enhancers and de-enhancers.

methodsA simulated population (n = 7680) equal in males and females, with/without smoking, aged 45-70 years, total cholesterol 3.5-7.0 mmol/L, high-density lipoprotein cholesterol 0.6-2.2 mmol/L, and systolic blood pressure 100-170 mmHg, was evaluated. High, intermediate, and low risks were determined using the Framingham Risk Score (FRS), Pooled Cohort Equation (PCE), four versions of Systematic Coronary Risk Evaluation 2 (SCORE2), and Multi-Ethnic Study of Atherosclerosis (MESA) algorithm (0-1000 Agatston Units).

resultsConcordance for the three levels of risk varied from 19% to 85%. Both sexes might be considered to have low, intermediate, or high risk depending on the algorithm applied, even with the same burden of risk factors. Only SCORE2 (High Risk and Very High Risk versions) identified equal proportions of males and females with high risk. Excluding MESA, the proportion with moderate risk was 25% (SCORE2, Very High Risk Region), 32% (FRS), 39% (PCE), and 45% (SCORE2, Low Risk Region).

conclusionRisk algorithms differ substantially in their estimation of risk, recommendations for statin treatment, and use of ancillary testing, even in identical patients. These results highlight the limitations of currently used risk-based approaches for addressing lipid-specific risk in primary prevention.

Indexed as

AtherosclerosisHydroxymethylglutaryl-CoA Reductase InhibitorsBlood PressureCholesterol, HDLFemaleHumansMaleRisk FactorsCholesterol, HDLHydroxymethylglutaryl-CoA Reductase InhibitorsCoronary artery calcium scoreFramingham Risk ScoreMulti-Ethnic Study of AtherosclerosisPooled Cohort EquationStatinsSystematic Coronary Risk Evaluation

Identifiers

PMID37638490
PMCPMC10771376

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.